Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 6.3% in October

Coya Therapeutics, Inc. (NASDAQ:COYA) was the target of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 186,100 shares, a growth of 6.3% from the September 30th total of 175,000 shares. Approximately 1.3% of the company’s stock are sold short. Based on an average daily trading volume, of 50,700 shares, the days-to-cover ratio is presently 3.7 days.

Institutional Trading of Coya Therapeutics

Several hedge funds have recently modified their holdings of the business. Gilbert & Cook Inc. purchased a new stake in shares of Coya Therapeutics during the 2nd quarter worth $61,000. Renaissance Technologies LLC acquired a new position in Coya Therapeutics during the second quarter worth about $101,000. GHP Investment Advisors Inc. acquired a new stake in shares of Coya Therapeutics during the 3rd quarter valued at approximately $169,000. Finally, Vanguard Group Inc. boosted its stake in shares of Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after acquiring an additional 750,338 shares in the last quarter. 39.75% of the stock is owned by institutional investors and hedge funds.

Coya Therapeutics Stock Down 2.6 %

NASDAQ:COYA traded down $0.19 during midday trading on Friday, reaching $7.04. The stock had a trading volume of 80,125 shares, compared to its average volume of 71,926. The stock has a market cap of $107.15 million, a P/E ratio of -10.00 and a beta of 0.58. Coya Therapeutics has a 12-month low of $4.40 and a 12-month high of $10.69. The firm has a fifty day simple moving average of $6.89 and a two-hundred day simple moving average of $7.10.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter. The firm had revenue of $3.43 million for the quarter. On average, sell-side analysts anticipate that Coya Therapeutics will post -1.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on COYA shares. Chardan Capital reiterated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Wednesday. HC Wainwright assumed coverage on shares of Coya Therapeutics in a research note on Monday, September 16th. They set a “buy” rating and a $18.00 target price for the company.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.